Psicotric

Quick links to important sections

Psicotric

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Psicotric

Property Description
Active ingredient Quetiapine Fumarate
Form Film-coated tablets (IR and XR)
Pharmacological class Atypical Antipsychotic (SGA)
Common use Modulating complex neural pathways in psychotic and mood disorders
Origin Synthetic compound (dibenzothiazepine derivative)

Psicotric is a prescription-only medicine (POM) used to help stabilize brain activity, which is foundational to managing severe mental health conditions. Its active substance, Quetiapine Fumarate, is classified as a synthetic psychopharmacological agent that requires monitoring by a healthcare professional.


What Type of Medicine is Psicotric (Quetiapine)?

Psicotric belongs to the pharmacological class known as atypical antipsychotics, or second-generation antipsychotics (SGAs). The core chemical structure of the active ingredient, Quetiapine, is categorized as a dibenzothiazepine derivative, a synthetic compound that acts as a central nervous system agent. This classification as an SGA is clinically recognized for its differential efficacy compared to older drug classes, influencing multiple neurotransmitter systems simultaneously for a broader therapeutic profile.


Composition and Available Formulations

The medication is a single-ingredient product containing Quetiapine Fumarate and is taken via the oral route of administration. Psicotric is supplied as film-coated tablets that are available in two primary types: the immediate-release (IR) formulation and the extended-release (XR) formulation. Quetiapine is utilized in both immediate and prolonged-release formulations, with the XR version utilizing a controlled release mechanism to ensure the compound is delivered gradually over a longer duration, aiming for sustained effects.


General Purpose of this Psychotropic Agent

The general purpose of this psychotropic agent is to stabilize mood and perception by modulating key brain chemicals. This action provides a broad stabilizing effect on the central nervous system and is intended to help rebalance signaling in the brain. By influencing the activity of neurotransmitters like dopamine and serotonin, the medication supports cognitive and emotional stability in individuals facing complex mood disorders and psychotic disorders.

Regulatory References

  1. MedlinePlus: Quetiapine Drug Information

What side effects are possible with Psicotric?

Possible Side Effects and Safety Information

The official safety profile of Psicotric (Quetiapine Fumarate), an atypical antipsychotic, is structured around categories established by government regulatory agencies to communicate documented risks and constraints. Adverse reactions are classified by frequency, ranging from Very Common to Rare.

Frequency and Systemic Groupings

Adverse effects listed as Very Common (ge 10%) in regulatory documents include somnolence (drowsiness), dizziness, dry mouth, weight gain, constipation, tachycardia, and postural hypotension (a drop in blood pressure upon standing). These effects are primarily grouped under Nervous System Disorders, Gastrointestinal Disorders, and Metabolic Disorders. Less common reactions may affect the blood and lymphatic system (e.g., leukopenia) and hepatic system (e.g., increased liver enzymes).

Serious and Contextual Safety Concerns

Official labels highlight the risk of serious, although generally uncommon, adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (involuntary movements), and severe Metabolic Changes such as Hyperglycemia (high blood sugar), which may lead to serious complications. Cardiovascular risks include QT Prolongation. Some effects, such as somnolence and orthostatic hypotension, are noted to be more likely during the initial dose-titration period.

Population-Specific Notes

Safety constraints are specific for certain populations: Elderly patients with dementia-related psychosis have an officially documented increased risk of death and cerebrovascular adverse reactions (e.g., stroke). In children and adolescents, a higher incidence of Extrapyramidal Symptoms (EPS) and elevated serum prolactin levels is observed. The regulatory framework requires regular monitoring of metabolic parameters (weight, glucose, lipids) and periodic eye examinations due to the documented risk of cataracts with long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Psicotric (Quetiapine Fumarate) is a serious situation requiring immediate medical attention. Regulatory documents confirm that acute overdosage may present with prominent central nervous system and cardiovascular effects.

Documented Overdose Manifestations

The most commonly reported clinical signs include severe drowsiness and somnolence, accompanied by cardiovascular changes such as tachycardia (rapid heart rate) and hypotension (low blood pressure). Other documented manifestations are dizziness and syncope (fainting), as well as miosis (pinpoint pupils).

Severe Outcomes and Emergency Action

Official labeling warns of the potential for severe or life-threatening outcomes, including coma, respiratory depression or failure, seizures, and serious cardiac arrhythmias such as QT prolongation. Cases of death have also been reported following acute overdosage. Individuals must contact emergency services or seek immediate medical attention for all suspected overdoses, as close medical supervision is required.

Management is symptomatic and supportive, focusing on maintaining a patent airway and ensuring adequate oxygenation and ventilation. No specific antidote is known for Quetiapine overdose, and continuous cardiovascular monitoring is necessary until the patient is stable. Special consideration is noted for elderly patients and those with pre-existing heart disease due to an increased risk of severe manifestations.

Therapeutic Uses of Psicotric

Psicotric (Quetiapine Fumarate) is a psychotropic agent used to provide supportive symptomatic relief across severe mental health conditions characterized by disruptions in mood and perception. It is commonly used in instances where symptoms intensify and create noticeable interference with daily stability. The medication is applied across therapeutic domains, including conditions associated with schizophrenia, bipolar disorder (managing both manic and depressive episodes), and is relevant for adjunctive treatment in adults with Major Depressive Disorder (MDD).

Therapeutic Benefit

Psicotric is applied in addressing challenging psychotic manifestations and stabilizing the intense, cyclical nature of bipolar mood episodes. In these scenarios, it helps address groups of symptoms such as hallucinations, delusions, disorganized thinking, excessive energy, and profound low mood. The core benefit assists with maintaining functional stability and supports a clearer perception of reality, which contributes to improved day-to-day comfort during symptomatic periods. In MDD, it is typically applied in situations where additional management of discomfort is required alongside antidepressant treatment, which contributes to easing the overall symptom load.


Quick Fact: Relief for Disruptive Manifestations

Psicotric is relevant for conditions characterized by episodic or fluctuating symptom patterns, providing symptomatic support during both acute episodes and long-term maintenance phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Psicotric (Quetiapine Fumarate) by Regulatory Status

Official government labeling strictly defines which populations are permitted to use Psicotric, which face restrictions, and which are absolutely excluded. Eligibility is primarily established for adults for all labeled indications. Specific indications are also approved for adolescents (13–17 years) with schizophrenia and children/adolescents (10–17 years) with bipolar mania.


Populations Who Must Not Use Psicotric

The medicine is contraindicated in patients with a known hypersensitivity to quetiapine or any of its components. Furthermore, it is not approved for use in elderly patients with dementia-related psychosis, as this population faces a documented increased risk of mortality.


Restricted and Conditional Use

Use is restricted in several populations. Psicotric is not recommended for children under 10 years or, under general European regulatory guidance, for adolescents under 18 due to insufficient long-term safety data. Patients with hepatic impairment or pre-existing cardiovascular disease should use the medicine with caution. Regarding pregnancy, use is conditional upon the potential benefit justifying the risk, and breastfeeding is not recommended by official authorities.

What should I know about interactions with other medicines?

The use of Psicotric (quetiapine) with certain other medicines is restricted due to the potential for clinically significant interactions that can alter the medicine’s concentration or increase the risk of specific adverse effects. Regulatory documentation provides clear constraints on co-administration.

Contraindicated Combinations

Psicotric must not be taken concurrently with the following products, as they can inhibit the enzyme system responsible for the medicine's metabolism, leading to a potentially significant increase in its concentration and risk of toxicity:

  • Medicines for HIV (specifically, certain protease inhibitors).
  • Azole-type medicines (used for fungal infections).
  • Macrolide antibiotics such as Erythromycin and Clarithromycin.
  • Nefazodone (a medicine for depression).

Required Cautions and Restrictions

  • Alcohol: Caution is required with alcohol consumption, as the combined effects may increase drowsiness.
  • Other Antidepressants: Co-administration with other antidepressant medicines may lead to a rare but potentially severe condition known as serotonin syndrome.
  • Grapefruit Juice: Patients are instructed not to drink grapefruit juice while taking this medicine, as it can affect how the medicine works.
  • Enzyme Inducers: Other medicines, such as Phenytoin or Carbamazepine, may decrease Psicotric's concentration in the body by inducing its metabolism, potentially making it less effective. Increased dosage may be required under careful monitoring.
  • Blood Pressure Lowering Agents: Concomitant use with other medicines that lower blood pressure may lead to an additive effect, increasing the risk of dizziness or fainting.

These mandated restrictions and warnings establish the boundaries for safe use and are designed to prevent dangerous changes in the drug's activity or concentration.

Mechanism of Action

Psicotric (quetiapine) primarily targets multiple G protein-coupled receptors in the central nervous system. Its core pharmacodynamic actions involve antagonism at the dopamine D2 receptors and the serotonin 5-HT2A receptors. The molecule exhibits a higher binding affinity for the 5-HT2A receptor relative to the D2 receptor.

D2 receptor antagonism reduces dopaminergic neurotransmission in select brain regions. Simultaneously, 5-HT2A receptor antagonism blocks the inhibitory control that 5-HT2A pathways exert over dopamine release in areas such as the prefrontal cortex, leading to a localized increase in dopamine outflow in these specific tracts. The compound and its active metabolite also act as partial agonists at the serotonin 5-HT1A receptor. Furthermore, Psicotric displays antagonism at histamine H1 receptors and alpha1-adrenergic receptors. The combination of these receptor interactions modulates the systemic monoaminergic signaling, resulting in altered postsynaptic neuronal excitability and neurotransmitter balance across diverse neural circuits.

Dosage and Administration Information

Psicotric (Quetiapine Fumarate) is administered via the oral route as film-coated tablets, available in Immediate-Release (IR) and Extended-Release (XR) formulations. The proper usage of the medicine is structured according to established protocols and is centered on a gradual dose titration strategy. Treatment initiation requires a low starting dose, such as 25 mg or 50 mg, which is then systematically increased over a period of days to reach the individualized maintenance dosage.

The administration schedule is dependent on the formulation. The XR tablet is administered once daily, usually in the evening. In contrast, the IR tablet is typically taken in divided doses throughout the day. Clinical parameters establish distinct maximum daily dosages that vary by condition, ranging from 300 mg for certain uses up to 800 mg per day for others.

Proper intake also includes specific instructions related to food and handling. The IR tablets offer flexibility and can be taken with or without food. However, the XR tablets should be taken without food or with a light meal and must be swallowed whole—they are not to be split, chewed, or crushed. Furthermore, specific protocols involve a lower starting dose and a slower titration schedule when prescribing the medication to older adults and individuals with hepatic impairment. Adherence to these procedural rules is central to the prescribed use protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Psicotric (Quetiapine Fumarate)


Evidence for Use in Schizophrenia

Research exploring Psicotric use in schizophrenia is primarily based on short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies was studied for periods of increased symptom activity in adults and adolescents and aimed to measure how symptoms evolved over defined time intervals. The key outcomes monitored were changes in the severity of psychotic symptoms and rates of symptom response.

High patient withdrawals before the study concluded may influence how easily results can be interpreted. Data for long-term outcomes, particularly for functional measures, remain limited beyond the initial short-term treatment window.


Evidence for Use in Bipolar Disorder

Psicotric was evaluated in conditions characterized by fluctuating or episodic manifestations, focusing on acute manic and acute depressive episodes. This research relies on RCTs designed to examine episodic or acute changes in mood symptoms.

Evidence for Bipolar Mania

Short-term RCTs, typically lasting three to 12 weeks, was studied for acute manic episodes in adults and adolescents. Research examined changes in manic symptoms severity using specialized rating scales. Comparative evidence is lacking to assess outcomes directly against all alternative active agents in the literature.

Evidence for Bipolar Depression

Research consists mainly of 8-week acute RCTs that studied depressive symptoms in adults with Bipolar I and Bipolar II Disorder. Studies monitored outcomes related to symptom intensity and the frequency of patients experiencing an acute switch into mania or hypomania. Research does not determine whether an individual will respond similarly; study results reflect the specific conditions under which they were conducted.


Evidence for Use in Major Depressive Disorder (MDD)

The evidence focuses on Psicotric's role as an adjunctive treatment alongside ongoing antidepressant therapy. These are primarily short-term RCTs of the extended-release (XR) formulation, typically lasting six to eight weeks. The trials studied patients who previously had an inadequate response to antidepressant monotherapy. Research describes short-term changes observed in this specific patient subgroup. The total sample sizes were modest compared to primary indications.


Research Gaps and Areas of Uncertainty

Areas where certainty remains low include comparative evidence against all alternative active agents. Additionally, long-term outcomes beyond the initial maintenance trials are not fully established, particularly regarding long-term stability over many years. Findings for certain subgroup populations are uncertain due to limited follow-up durations.

Key Studies & References European Medicines Agency (EMA) - Public Assessment Report for Quetiapine

Frequently Asked Questions (FAQ)

Common questions about Psicotric (FAQ)


Q: How quickly does Psicotric start working after the first dose?

A: Studies and official information indicate that a change in symptoms, such as for major depressive episodes, has been observed as early as within the first week of starting treatment. Initial effects for conditions like mania may also be noticed within days. Clinical trials indicate that continued improvement is typically observed over the following weeks.


Q: What is the typical timeframe to feel the full effects of Psicotric?

A: The drug is expected to reach stable levels in the blood within about two days of starting therapy. Clinical trials designed to measure the full change in symptoms typically run for several weeks, often between 3 to 12 weeks for acute conditions. Patients are advised to continue treatment as directed by their healthcare provider.


Q: Does Psicotric cause weight gain or weight loss?

A: Official safety documents list weight gain as a documented adverse reaction and a Very Common side effect. Official product information does not commonly list weight loss as an adverse reaction for this medication.


Q: What foods or drinks should be avoided while on Psicotric?

A: Patients are officially instructed not to drink grapefruit juice while taking this medicine, as it can interfere with how the drug works. Additionally, regulatory warnings advise caution with alcohol consumption, as the combination may significantly increase feelings of drowsiness.


Q: Are there any herbal supplements that interact negatively with Psicotric?

A: Yes, official drug information documents mention interactions with the herbal product St. John's Wort. Taking this supplement can decrease the medicine's concentration in the body. If using any supplements, it is important to review them with a healthcare provider.


Q: How long can a person safely stay on Psicotric?

A: Regulatory documents on maintenance treatment recommend that patients should be periodically reassessed by a healthcare professional. This regular check-in helps to determine the continuing need for the medication and to ensure the dose remains appropriate. Patients are advised to continue treatment as directed by their healthcare provider.


Q: Does Psicotric affect a person's ability to drive or operate machinery?

A: Yes, official warnings state that the medicine may cause drowsiness and dizziness. These effects can impair judgment, clear thinking, and motor skills. Official warnings advise patients to use caution and avoid driving or operating complex machinery until they know how the medication affects them.


Q: What should I do if I miss a dose of Psicotric?

A: Official guidance suggests that if a person has been off the medicine for more than one week, they may need to follow the initial lower dosing schedule again to restart safely. For specific guidance regarding a single missed dose, patients should refer to the instructions provided by a healthcare professional.


Q: Are the side effects of Psicotric permanent or do they go away?

A: Side effects vary. Some, such as drowsiness and orthostatic hypotension, are noted to be more common during the initial dose-titration period and may lessen over time. However, other serious adverse effects, such as Tardive Dyskinesia (involuntary movements), can be potentially long-lasting or permanent.


Q: Where can I find reliable, independent studies on Psicotric?

A: Reliable information can be accessed through documents published by government regulatory health authorities. These include drug labels and patient guides from bodies such as the FDA (U.S.), EMA (Europe), and patient resources like NIH MedlinePlus.


Q: Is Psicotric known to be addictive?

A: The official label states that the active ingredient, Quetiapine Fumarate, is not a controlled substance under U.S. federal regulation. This classification indicates a low potential for abuse.


Q: Can Psicotric cause changes in appetite?

A: Yes, official drug safety profiles list increased appetite as a documented adverse reaction in both adults and in children and adolescents who take this medication.


Q: What happens if you accidentally take two doses of Psicotric close together?

A: Taking more than the prescribed amount is considered an overdosage. The documented signs of overdosage may include severe drowsiness and a fast heartbeat. Official documentation describes the management of overdosage as supportive care, typically provided in a medical setting.


Q: How often do people need blood tests while on Psicotric?

A: Official guidelines require regular monitoring of metabolic parameters, such as blood sugar and lipids. Periodic eye examinations for cataracts are also recommended at the start of treatment and then at approximately six-month intervals during chronic treatment.


Q: Does Psicotric affect memory or concentration?

A: Official warnings note the potential for cognitive and motor impairment. Side effects like drowsiness and fatigue are common, and these can interfere with a person's ability to focus or concentrate.


Q: Does Psicotric interact with alcohol, even in small amounts?

A: Yes, official regulatory warnings advise that alcoholic beverages should be limited. Alcohol can potentiate, or increase, the drug's effects on the brain, significantly increasing the risk of drowsiness and impairing motor skills, even with small amounts of alcohol.


Q: Will I experience withdrawal symptoms if I stop taking Psicotric abruptly?

A: Official safety information reports that withdrawal reactions have occurred following the sudden stopping of the medication. These reactions may include symptoms such as nausea, vomiting, and insomnia (difficulty sleeping). Official warnings advise patients against stopping the medicine suddenly due to the risk of experiencing these reactions.


Q: What is the recommended storage temperature for Psicotric?

A: Official instructions state that the medicine should be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F). It is also important to protect the medication from excessive heat and moisture.


Q: Is Psicotric generally considered safe for long-term use?

A: While the medicine is often used for long-term management, the safety profile includes potential long-term risks that require ongoing monitoring. These include the possibility of cataracts, Tardive Dyskinesia, and metabolic changes like high blood sugar and weight gain.


Q: What are the rare but serious side effects of Psicotric I should know about?

A: Official labels highlight several serious, though generally uncommon, risks. These include Neuroleptic Malignant Syndrome (NMS), which is a rare, severe reaction; Tardive Dyskinesia (involuntary movements); and severe Metabolic Changes such as high blood sugar.


Q: Is a person on Psicotric considered to be 'dependent' on the drug?

A: The drug is officially stated to not be a controlled substance and has low abuse potential. However, because the body adapts to the medicine, official warnings advise against abrupt discontinuation due to the risk of experiencing withdrawal-like reactions.


Q: Is it safe to exercise heavily while taking Psicotric?

A: Official medication guides warn patients to avoid getting overheated or dehydrated. Because the drug can affect the body's temperature regulation, it is recommended to drink plenty of fluids, particularly during strenuous exercise or in hot weather.

How should Psicotric be stored and disposed of?

The storage and disposal of Psicotric ( Quetiapine Fumarate) must adhere strictly to regulatory requirements for stability and safety.

Scope Item Official Regulatory Statement
Labeled storage temperature requirements Store at room temperature, generally between 20 C and 25 C (68 F and 77 F).
Light/moisture protection requirements Protect from excessive heat and moisture (do not store in the bathroom).
Packaging-related storage rules Keep the medication in the original container and ensure the container is tightly closed.
Child-protection storage requirements It is mandatory to keep this medication out of the sight and reach of children.

For disposal, official guidance prioritizes using a drug take-back program. If this option is unavailable, unused tablets must be removed from the container, mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed bag or container, and then discarded in the household trash. The tablets must not be crushed for disposal, and environmental release must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Psicotric found in:

A-Z Index: